RecruitingPhase 3NCT06750094
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Sponsor: Janssen Research & Development, LLC
Penn Wynne, PA · Philadelphia, PA · +68 more sites